0.9500USD+2.15%Mkt Cap: 11.76M USDP/E: —Last update: 2026-05-22
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead prod…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap11.76M USD
Enterprise Value-34.22M USD
Revenue (TTM)123.30K USD
Gross Profit-6.92M USD
Net Income (TTM)-12.60M USD
Revenue/Share0.0140 USD
Last Price0.9500 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.18
PEG—
EV/EBITDA2.73
EV/Revenue-277.57
P/S93.40
P/B0.27
EPS (TTM)-1.49
EPS (Forward)-0.79
52W Range
0.548024% of range2.220
52W High2.220 USD
52W Low0.5480 USD
Profitability
Gross Margin0.00%
Oper. Margin-10202.01%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-101.27%
ROA-79.08%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-12.89M USD
CapEx (TTM)—
FCF Margin-4548.21%
FCF Yield-47.67%
Net Debt-46.47M USD
Net Debt/EBITDA3.70
Balance Sheet
Debt/Equity—
Current Ratio8.92
Quick Ratio8.77
Book Value/Sh3.471 USD
Cash/Share3.752 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateFeb 13, 2023
Analyst Consensus
Rating1.3 (Strong Buy)
Target (Mean)4.300 USD
Target Range1.200 USD – 6.000 USD
# Analysts4
Ownership
Shares Out.12.38M
Float8.57M
Insiders11.56%
Institutions18.13%
Short Interest
Short Ratio0.1d
Short % Float0.88%
Short % Out.0.83%
Shares Short103.02K
Short (prev mo.)640.35K
Technical
SMA 500.8250 (+15.1%)
SMA 2001.093 (-13.1%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)258.28K
Avg Vol (10d)250.91K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—